Search

Tocilizumab: Increase in alanine aminotransferase level: 3 case reports B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event In retrospective cohort study of 9 patients admitted to the University Hospital of Burgos, Spain from 1 April 2020 to 11 May 2020, three men aged 48-67 years were described, who had increase in alanine aminotransferase level following off label treatment with tocilizumab for COVID-19-related acute respiratory distress syndrome [ I not all routes and dosages stated; duration of treatments to reactions onsets not stated i ]. Case 1: A 67-year-old man had increase in alanine aminotransferase level following off label treatment with tocilizumab for COVID-19-related acute respiratory distress syndrome: The ex-smoker man admitted to the hospital due to COVID-19-related acute respiratory distress syndrome and received off label treatment with hydroxychloroquine 400 mg/12 hours on day 1 followed by 200 mg/ 12 hours for 5 days, azithromycin 500 mg/ 24 hours for 7 days and then every 48 hours for 14 days, IV bolus methylprednisolone 250 mg/day for 3 days and 2 doses of IV tocilizumab. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 49-year-old man developed QTc prolongation during off label treatment with azithromycin and hydroxychloroquine for COVID-19. The previously healthy man presented with COVID-19 infection, and required mechanical ventilation and extracorporeal membrane oxygenation due to severe hypoxemia and acute respiratory distress syndrome (ARDS). Due prolonged QTc, the man's treatment with azithromycin and hydroxychloroquine was discontinued after 2 days. [Extracted from the article]